APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Outlook and Growth Opportunities 2026

Report ID 173961260420 December 2025191 pages

Choose your research edition.

Industry ResearchAge Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market include Novartis, Roche, Bayer Healthcare, Regeneron Pharmaceuticals, Neurotech Pharmaceuticals and Allergan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Segment by Company

Novartis

Roche

Bayer Healthcare

Regeneron Pharmaceuticals

Neurotech Pharmaceuticals

Allergan

Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Segment by Type

Macular Degeneration Drugs

Diabetic Retinopathy Drugs

Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Segment by Application

50-60 Years Old

60-70 Years Old

Others

Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs industry.

Chapter 3: Detailed analysis of Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Trends Table 2. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Drivers Table 3. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Opportunities and Challenges Table 4. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Restraints Table 5. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Share by Company (2021-2026) Table 7. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume by Company (W Tons) & (2021-2026) Table 8. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Company, Product Type & Application Table 13. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Macular Degeneration Drugs Table 18. Significant Companies of Diabetic Retinopathy Drugs Table 19. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (W Tons) Table 20. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume by Type (2021-2026) & (W Tons) Table 21. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume by Type (2027-2032) & (W Tons) Table 22. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type (2021-2026) Table 28. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of 50-60 Years Old Table 30. Significant Companies of 60-70 Years Old Table 31. Significant Companies of Others Table 32. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (W Tons) Table 33. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume by Application (2021-2026) & (W Tons) Table 34. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume by Application (2027-2032) & (W Tons) Table 35. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application (2021-2026) Table 41. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application (2027-2032) Table 42. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Tons) Table 43. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales by Region (2021-2026) & (W Tons) Table 44. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Market Share by Region (2021-2026) Table 45. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales by Region (2027-2032) & (W Tons) Table 46. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Market Share by Region (2027-2032) Table 47. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Region (2021-2026) Table 50. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Region (2027-2032) Table 52. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Average Price (US$/Ton) by Region (2021-2026) Table 53. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Average Price (US$/Ton) by Region (2027-2032) Table 54. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Tons) Table 55. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales by Country (2021-2026) & (W Tons) Table 57. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Market Share by Country (2021-2026) Table 58. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales by Country (2027-2032) & (W Tons) Table 59. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Market Share by Country (2027-2032) Table 60. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Market Share by Country (2027-2032) Table 64. Novartis Company Information Table 65. Novartis Business Overview Table 66. Novartis Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 67. Novartis Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Portfolio Table 68. Novartis Recent Development Table 69. Roche Company Information Table 70. Roche Business Overview Table 71. Roche Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 72. Roche Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Portfolio Table 73. Roche Recent Development Table 74. Bayer Healthcare Company Information Table 75. Bayer Healthcare Business Overview Table 76. Bayer Healthcare Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 77. Bayer Healthcare Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Portfolio Table 78. Bayer Healthcare Recent Development Table 79. Regeneron Pharmaceuticals Company Information Table 80. Regeneron Pharmaceuticals Business Overview Table 81. Regeneron Pharmaceuticals Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 82. Regeneron Pharmaceuticals Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Portfolio Table 83. Regeneron Pharmaceuticals Recent Development Table 84. Neurotech Pharmaceuticals Company Information Table 85. Neurotech Pharmaceuticals Business Overview Table 86. Neurotech Pharmaceuticals Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 87. Neurotech Pharmaceuticals Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Portfolio Table 88. Neurotech Pharmaceuticals Recent Development Table 89. Allergan Company Information Table 90. Allergan Business Overview Table 91. Allergan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 92. Allergan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Portfolio Table 93. Allergan Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Distributors List Table 97. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Image Figure 2. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales (2021-2032) & (W Tons) Figure 5. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Macular Degeneration Drugs Image Figure 10. Diabetic Retinopathy Drugs Image Figure 11. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (W Tons) Figure 12. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type (2021-2032) Figure 17. 50-60 Years Old Image Figure 18. 60-70 Years Old Image Figure 19. Others Image Figure 20. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (W Tons) Figure 21. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Tons) Figure 27. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Macular Degeneration Drugs
  • Diabetic Retinopathy Drugs
Applications
  • 50-60 Years Old
  • 60-70 Years Old
  • Others
Companies covered
  • Novartis
  • Roche
  • Bayer Healthcare
  • Regeneron Pharmaceuticals
  • Neurotech Pharmaceuticals
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Dynamics
  1. 2.1 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Trends
  2. 2.2 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Drivers
  3. 2.3 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Opportunities and Challenges
  4. 2.4 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Restraints
3 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market by Company
  1. 3.1 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Company Ranking (2024-2026)
  6. 3.6 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Company Product Type and Application
  8. 3.8 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market by Type
  1. 4.1 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Type Introduction
  2. 4.1.1 Macular Degeneration Drugs
  3. 4.1.2 Diabetic Retinopathy Drugs
  4. 4.2 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume by Type
  5. 4.2.1 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Type
  9. 4.3.1 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type (2021-2032)
5 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market by Application
  1. 5.1 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Application Introduction
  2. 5.1.1 50-60 Years Old
  3. 5.1.2 60-70 Years Old
  4. 5.1.3 Others
  5. 5.2 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume by Application
  6. 5.2.1 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Application
  10. 5.3.1 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application (2021-2032)
6 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Regional Sales and Value Analysis
  1. 6.1 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales by Region (2027-2032)
  5. 6.3 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Country, 2025 VS 2032
7 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales by Country (2027-2032)
  6. 7.4 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Roche Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 Bayer Healthcare
  14. 8.3.1 Bayer Healthcare Company Information
  15. 8.3.2 Bayer Healthcare Business Overview
  16. 8.3.3 Bayer Healthcare Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Healthcare Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Portfolio
  18. 8.3.5 Bayer Healthcare Recent Developments
  19. 8.4 Regeneron Pharmaceuticals
  20. 8.4.1 Regeneron Pharmaceuticals Company Information
  21. 8.4.2 Regeneron Pharmaceuticals Business Overview
  22. 8.4.3 Regeneron Pharmaceuticals Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Regeneron Pharmaceuticals Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Portfolio
  24. 8.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 8.5 Neurotech Pharmaceuticals
  26. 8.5.1 Neurotech Pharmaceuticals Company Information
  27. 8.5.2 Neurotech Pharmaceuticals Business Overview
  28. 8.5.3 Neurotech Pharmaceuticals Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Neurotech Pharmaceuticals Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Portfolio
  30. 8.5.5 Neurotech Pharmaceuticals Recent Developments
  31. 8.6 Allergan
  32. 8.6.1 Allergan Company Information
  33. 8.6.2 Allergan Business Overview
  34. 8.6.3 Allergan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Allergan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Portfolio
  36. 8.6.5 Allergan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Value Chain Analysis
  2. 9.1.1 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Mode & Process
  6. 9.2 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Distributors
  9. 9.2.3 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst